Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Phase 3

Not yet recruiting

Conditions: Pleuropulmonary Blastoma

Interventions: Procedure: Biospecimen Collection
Other: Patient Observation
Procedure: Computed Tomography
Procedure: Bone Scan
Drug: Cyclophosphamide
Biological: Dactinomycin
Procedure: Resection
Procedure: Ultrasound Imaging
Drug: Dexrazoxane
Drug: Vincristine
Drug: Doxorubicin
Procedure: Echocardiography
Drug: Ifosfamide
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography
Drug: Topotecan

First Posted Date: 2024-10-18

Last Posted Date: 2024-12-05

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 110

Registration Number: NCT06647953

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Phase 2

Recruiting

Conditions: Neuroblastoma
Childhood Neuroblastoma
High-risk Neuroblastoma

Interventions: Biological: DANYELZA
Biological: Sargramostim
Drug: Cytoxan
Drug: Topotecan
Drug: Vincristine
Drug: Doxorubicin
Drug: Ifosfamide
Drug: Etoposide
Drug: Carboplatin
Drug: Irinotecan
Drug: Temozolomide

First Posted Date: 2024-07-30

Last Posted Date: 2024-11-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT06528496

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Phase 2

Recruiting

Conditions: Relapsed/Refractory Large B-Cell Lymphoma

Interventions: Drug: Linperlisib
Drug: Rituximab
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Dexamethasone
Drug: Cisplatin
Drug: Ara-C
Drug: Vinorelbine
Drug: Mitoxantrone hydrochloride liposome

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 89

Registration Number: NCT06489808

Locations: 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Phase 2

Not yet recruiting

Conditions: Leiomyosarcoma
Liposarcoma
Synovial Sarcoma
Angiosarcoma
Undifferentiated Pleomorphic Sarcoma
Epithelioid Sarcoma
Malignant Peripheral Nerve Sheath Tumors
Fibrosarcoma
Pleomorphic Rhabdomyosarcoma
Endometrial Stromal Sarcoma

Interventions: Drug: Doxorubicin
Biological: MASCT-I
Drug: Ifosfamide

First Posted Date: 2024-02-26

Last Posted Date: 2024-02-26

Lead Sponsor: HRYZ Biotech Co.

Target Recruit Count: 148

Registration Number: NCT06277154

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1

Recruiting

Conditions: Non-rhabdomyosarcoma
Adipocytic Neoplasm
Liposarcoma

Interventions: Procedure: Surgical resection
Radiation: Proton beam radiation therapy
Drug: Pazopanib
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Selinexor

First Posted Date: 2024-02-02

Last Posted Date: 2024-04-03

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 139

Registration Number: NCT06239272

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3

Recruiting

Conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL)

Interventions: Drug: Odronextamab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Rituximab
Drug: Dexamethasone
Drug: Cisplatin
Drug: Cytarabine
Drug: Gemcitabine

First Posted Date: 2024-01-30

Last Posted Date: 2024-12-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 216

Registration Number: NCT06230224

Locations: 🇨🇳
Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan
🇹🇷
VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

and more 54 locations

A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

Phase 2

Recruiting

Conditions: B-cell Non Hodgkin Lymphoma

Interventions: Drug: Odronextamab
Biological: CAR T-cells (TBC)
Drug: Loncastuximab tesirine
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Etoposide Phosphate
Drug: Dexamethasone

First Posted Date: 2023-08-14

Last Posted Date: 2024-11-08

Lead Sponsor: University of Birmingham

Target Recruit Count: 210

Registration Number: NCT05991388

Locations: 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧
Royal Manchester Children's Hospital, Manchester, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, United Kingdom